On Monday, Shares of Horizon Pharma PLC (NASDAQ:HZNP), lost -1.95% to $19.13. The stock attained the volume of 2.36 million shares.
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Chairman, President and Chief Executive Officer Timothy P. Walbert, received the Chicago Area Entrepreneurship Hall of Fame Award from the University of Illinois at Chicago’s (UIC) Institute for Entrepreneurial Studies (IES). The award recognizes distinguished business people who have demonstrated their entrepreneurial talent by fostering a thriving, diversified economic engine in Chicago and have enhanced Chicago’s communities.
Walbert joined Horizon Pharma in June 2008 as president and chief executive officer, and he has served as chairman of the company’s board of directors since 2010. In that time, he has grown Horizon Pharma from one employee working out of a coffee shop to more than 700 global employees with offices in four countries. Walbert also serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and sits on the boards of directors of XOMA Corporation (NASDAQ: XOMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, which is the World Business Chicago’s innovation business development community, and the Greater Chicago Arthritis Foundation. He is also a member of the Illinois Innovation Council.
Chicago Area Entrepreneurship Hall of Fame Award nominees took part in personal interviews with a panel of judges and members of the Chicago Area Entrepreneurship Hall of Fame, who evaluated each nominee and selected winners based on their social and commercial contributions to strengthen Chicago’s economic environment and enhance the surrounding communities. The award was presented during the IES’ 30th Chicago Area Entrepreneurship Hall of Fame Dinner and Awards Ceremony on Thursday, October 8, 2015.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
At the end of Monday’s trade, Shares of Amedica Corporation (NASDAQ:AMDA), inclined 1.83% to $0.306.
Amedica Corporation (AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is happy to declare that it has reached a joint development agreement with Worthington dental technology to provide access to the Company’s silicon nitride technology platform to develop, prototype and manufacture the patented Worthington dental implant system.
Following the terms of the agreement, Amedica will assist Worthington in the development and commercialization of the Worthington dental implant system and devices. Additionally, Amedica has engaged Worthington as a dental expert to support Amedica in its efforts to expand the use of silicon nitride to additional original equipment manufacturer dental partners.
Amedica’s micro-composite silicon nitride biomaterial is a breakthrough ceramic containing potential anti-bacterial and favorable bone growth properties. Its surface texture and hydrophilic nature attract both osteoblasts and physiologic proteins to ensure reliable osteointegration, while its surface biochemistry inhibits bacterial biofilm adhesion. This combination of optimal material properties is unique to Amedica’s silicon nitride material platform.
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America.
Finally, Shares of Ascent Solar Technologies, Inc. (NASDAQ:ASTI), ended its last trade with 2.11% gain, and closed at $0.194.
Ascent Solar Technologies, Inc. (NASDAQ:ASTI), a provider of lightweight, flexible photovoltaic (PV) solutions, declared that the Company’s newest rugged fully-integrated photovoltaic power solution, the MilPak™ E, has met the grueling conditions required under MIL-STD-810G testing and has been selected as a finalist for the forthcoming R&D 100 Awards in two product categories, counting the exciting new “Market Disruptor” category.
In addition, the MilPak™ E has also been selected to present to the U.S. Military, Corporate, and Investment Leadership at the Defense Energy Innovation Summit and Showcase on December 1-3, 2015 in Austin, Texas.
The MilPak™ E is a fully integrated mobile power solution that comprises a foldable photovoltaic blanket with an attached waterproof battery case that houses a maximum peak power tracker, 86.5 watt hours of power storage with battery administration circuitry, a 55 watt 24 volt power circuit, and two high-current USB circuits.
Ascent Solar Technologies, Inc., a development stage company, designs and manufactures photovoltaic integrated consumer electronics; and portable power applications for commercial and military users.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
